Skip to main content

Todos Medical, Care GB to Form JV to Commercialize Cancer Dx Platform

NEW YORK – Todos Medical announced Wednesday it has expanded its partnership with Care GB Plus to develop and commercialize its Todos Biochemical Infrared Analyses cancer diagnostic platform in Europe, Israel, and Africa. 

Under the expanded agreement, the companies will form a joint venture for the tests. Care GB will own 67 percent of the venture and Todos will own the remaining stake. The original agreement in 2018 was for the development and commercialization of its cancer tests in Israel alone. Rehovot, Israel-based Todos will retain all rights to territories outside of Europe, Israel, and Africa. 

Care GB will assume all costs for product development and algorithm optimization responsibilities that are necessary to commercialize the test. As part of the deal, Todos' Chief Technology Officer Uzi Zelig will become CTO of the joint venture. Care GB will also provide "full financial support" for the laboratory and data generation requirements to support Orot Luces, Todos' other commercial partner, in commercial distribution efforts in Romania.

The TBIA platform uses peripheral blood analysis to look for biochemical changes in blood mononuclear cells and plasma to examine cancer's influence on the immune system. The firm's two cancer screening tests, TMB-1 and TMB-2, have received CE marking, and Todos is developing multiple SARS-CoV-2 tests.